Literature DB >> 34078723

Vascular cell adhesion molecule-1 in rheumatoid arthritis patients: Relation to disease activity, oxidative stress, and systemic inflammation.

Heba R Salem1, Enas S Zahran1.   

Abstract

OBJECTIVES: To evaluate the potential role of vascular cell adhesion molecule-1 (VCAM-1), an endothelial factor, in endothelial dysfunction in rheumatoid arthritis (RA) patients, and to determine its relation to disease activity, oxidative stress, and inflammatory markers.
METHODS: This study was designed as a cross-sectional case-control study. One-hundred patients with RA were selected from out-patient clinics of Menoufia University Hospital, Menoufia, Egypt from May 2019 to May 2020. Fifty patients previously diagnosed with RA for more than 6 months were included as Group I, and fifty patients newly diagnosed with RA were included as Group II. Fifty healthy age- and gender-matched individuals were evaluated as the control group (Group III). Complete blood count, random blood glucose, erythrocyte sedimentation rate (ESR), lipid profile, rheumatoid factor, anti-cyclic citrullinated peptide antibodies, serum levels of urea, creatinine, C-reactive protein, VCAM-1, malondialdehyde, and total antioxidant capacity were determined.
RESULTS: Patients with RA showed significantly higher serum VCAM-1, malondialdehyde, ESR, C-reactive protein, triglycerides, total cholesterol, low-density lipoprotein, and atherogenic index levels than the control group. Also, they showed significantly lower total antioxidant capacity and high-density lipoprotein levels than control group. A significant positive correlation between serum VCAM-1 with disease activity, serum malondialdehyde, ESR, and C-reactive protein was observed. Also, a significant negative correlation between serum VCAM-1 and total antioxidant capacity was present.
CONCLUSION: Serum VCAM-1 increases in RA, and it correlates with disease activity, oxidative stress, and inflammatory markers. Copyright: © Saudi Medical Journal.

Entities:  

Keywords:  VCAM-1; endothelial dysfunction; oxidative stress; rheumatoid arthritis

Mesh:

Substances:

Year:  2021        PMID: 34078723      PMCID: PMC9149717          DOI: 10.15537/smj.2021.42.6.20200753

Source DB:  PubMed          Journal:  Saudi Med J        ISSN: 0379-5284            Impact factor:   1.422


  40 in total

Review 1.  Vascular adhesion molecules in atherosclerosis.

Authors:  Elena Galkina; Klaus Ley
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-08-02       Impact factor: 8.311

2.  The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

Authors:  M Dobiásová; J Frohlich
Journal:  Clin Biochem       Date:  2001-10       Impact factor: 3.281

Review 3.  Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications.

Authors:  Bryant R England; Geoffrey M Thiele; Daniel R Anderson; Ted R Mikuls
Journal:  BMJ       Date:  2018-04-23

4.  Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression.

Authors:  M D Smith; J Slavotinek; V Au; H Weedon; A Parker; M Coleman; P J Roberts-Thomson; M J Ahern
Journal:  Rheumatology (Oxford)       Date:  2001-09       Impact factor: 7.580

5.  Subendocardial viability ratio in patients with rheumatoid arthritis: comparison with healthy controls and identification of prognostic factors.

Authors:  Panagiota Anyfanti; Areti Triantafyllou; Eugenia Gkaliagkousi; Georgios Triantafyllou; Nikolaos Koletsos; Sophia Chatzimichailidou; Panagiotis Panagopoulos; Ioannis Botis; Spyros Aslanidis; Stella Douma
Journal:  Clin Rheumatol       Date:  2017-04-28       Impact factor: 2.980

6.  Alterations in intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) in human endothelial cells.

Authors:  Khaled Habas; Lijun Shang
Journal:  Tissue Cell       Date:  2018-09-12       Impact factor: 2.466

Review 7.  An Overview of the Extraarticular Involvement in Rheumatoid Arthritis and its Management.

Authors:  Subham Das; Prasanta Padhan
Journal:  J Pharmacol Pharmacother       Date:  2017 Jul-Sep

Review 8.  Endothelial dysfunction in chronic inflammatory diseases.

Authors:  Curtis M Steyers; Francis J Miller
Journal:  Int J Mol Sci       Date:  2014-06-25       Impact factor: 5.923

9.  Targeting Tumor Necrosis Factor-α with Adalimumab: Effects on Endothelial Activation and Monocyte Adhesion.

Authors:  Raghav Oberoi; Jutta Schuett; Harald Schuett; Ann-Kathrin Koch; Maren Luchtefeld; Karsten Grote; Bernhard Schieffer
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

10.  Endothelial Dysfunction in Rheumatoid Arthritis: Mechanistic Insights and Correlation with Circulating Markers of Systemic Inflammation.

Authors:  Perle Totoson; Katy Maguin-Gaté; Maude Nappey; Daniel Wendling; Céline Demougeot
Journal:  PLoS One       Date:  2016-01-13       Impact factor: 3.240

View more
  4 in total

1.  Serum catestatin levels in patients with rheumatoid arthritis.

Authors:  Petra Simac; Dijana Perkovic; Ivona Bozic; Marijana Matijas; Katarina Gugo; Dinko Martinovic; Josko Bozic
Journal:  Sci Rep       Date:  2022-03-09       Impact factor: 4.379

2.  Comment on: Vascular cell adhesion molecule-1 in rheumatoid arthritis.

Authors:  Ali S Jawad
Journal:  Saudi Med J       Date:  2021-08       Impact factor: 1.422

3.  TNF-α Inhibitors in Combination with MTX Reduce Circulating Levels of Heparan Sulfate/Heparin and Endothelial Dysfunction Biomarkers (sVCAM-1, MCP-1, MMP-9 and ADMA) in Women with Rheumatoid Arthritis.

Authors:  Anna Szeremeta; Agnieszka Jura-Półtorak; Aleksandra Zoń-Giebel; Krystyna Olczyk; Katarzyna Komosińska-Vassev
Journal:  J Clin Med       Date:  2022-07-20       Impact factor: 4.964

Review 4.  Treatment of Cardiovascular Disease in Rheumatoid Arthritis: A Complex Challenge with Increased Atherosclerotic Risk.

Authors:  Saba Ahmed; Benna Jacob; Steven E Carsons; Joshua De Leon; Allison B Reiss
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.